Abstract 5802: An orally available small molecule JMBI-001 elicits MYC-synthetic lethality and anti-tumor immunity by disabling MKLP2-mediated cellular processes

杀伤力 合成致死 免疫 癌症研究 小分子 细胞免疫 医学 药理学 化学 免疫系统 免疫学 生物 毒理 生物化学 基因 DNA修复
作者
Ting Zhang,Qiong Shi,Julia Kalashova,Xumei Liu,Xiaohu Zhou,Chenglu Yang,Long Yan,Hongmei Li,Jinhua Li,Lv Gang,Duo Yu,Xuejiao Jiang,Shenqiu Zhang,Jing Zhang,Hongfang Liu,Dun Yang
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 5802-5802
标识
DOI:10.1158/1538-7445.am2024-5802
摘要

Abstract The MYC oncogene, a pivotal regulator of various cellular processes, is deregulated in approximately 70 % of human malignancies. Mitotic Kinesin-like Protein 2 (MKLP2) plays a versatile role in both interphase and mitosis and has emerged as a significant prognostic indicator and therapeutic target in cancer. The undruggability of MYC and the scarcity of MKLP2 inhibitors, however, have impeded clinical translation. Our development of JMBI-001, a potent and orally bioavailable small-molecule compound, overcomes these barriers. JMBI-001 elicits loss of function phenotypes in MKLP2 and a synthetic lethal interaction with MYC overexpression. Extensive kinome and safety profiling have revealed no significant off-target effects, and the compound is well-tolerated in long-term animal studies. In preclinical models, JMBI-001 has demonstrated an average tumor growth inhibition rate of 75 % across more than 20 MYC-overexpressing tumor models, including those in the stomach, lung, colon, liver, breast, kidney, skin, and hematopoietic system. Its anti-tumor activity positively correlates with high MYC abundance, aligning with the selective eradication of cells with abundant MYC both in vitro and in vivo. Notably, JMBI-001 also robustly stimulates systemic anti-tumor immunity, enhancing NK and CD3+ T cell infiltration in tumors of syngeneic cancer models. Moreover, additive or synergistic effects have been observed when combined with anti-PD1 therapy even in tumors refractory to the immune checkpoint blockade (ICB) therapy. The dual therapeutic actions of JMBI-001 stem from its disruption of MKLP2 functionalities, leading to anomalies, such as Golgi fragmentation in interphase and multipolarity in pro-metaphase. These disruptions lead to two key outcomes: apoptosis and immunogenic cell death, marked by secreted ATP, released high mobility group protein B1 (HMGB1), and surface-exposed calreticulin. These abnormalities, primed and amplified by deregulated MYC, are not observed in non-transformed cells, suggesting their potential as pharmacodynamic markers for monitoring JMBI-001's activity in vivo. In conclusion, JMBI-001 represents a novel class of anticancer agents that simultaneously triggers MYC synthetic lethality and anticancer immunity by targeting MKLP2-mediated cellular processes. Its unique mechanisms of action, exceptional bioavailability, potency at low nanomolar concentrations, wide-spectrum efficacy, and favorable safety profile establish JMBI-001 as a promising clinical study-ready drug candidate for treating MYC-driven cancers. Citation Format: Ting Zhang, Qiong Shi, Julia Kalashova, Xumei Liu, Xiaohu Zhou, Chenglu Yang, Yan Long, Hongmei Li, Jinhua Li, Gang Lv, Duo Yu, Xuejiao Jiang, Shenqiu Zhang, Jing Zhang, Hong Liu, Dun Yang. An orally available small molecule JMBI-001 elicits MYC-synthetic lethality and anti-tumor immunity by disabling MKLP2-mediated cellular processes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5802.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Xk发布了新的文献求助10
2秒前
小蘑菇的应助被kitten采纳,获得10
4秒前
yshog完成签到,获得积分10
5秒前
yuan完成签到,获得积分10
5秒前
istor发布了新的文献求助10
5秒前
5秒前
布式鹿炽完成签到,获得积分10
6秒前
7秒前
柚子完成签到,获得积分20
7秒前
Cyber_relic完成签到,获得积分10
7秒前
无私鹤轩发布了新的文献求助10
8秒前
无私鹤轩发布了新的文献求助10
8秒前
风吹麦浪发布了新的文献求助10
8秒前
无私鹤轩发布了新的文献求助10
9秒前
无私鹤轩发布了新的文献求助10
9秒前
无私鹤轩发布了新的文献求助10
9秒前
Spike完成签到,获得积分10
9秒前
无私鹤轩发布了新的文献求助10
10秒前
无私鹤轩发布了新的文献求助10
10秒前
10秒前
无私鹤轩发布了新的文献求助10
10秒前
信仰完成签到,获得积分10
11秒前
容止完成签到,获得积分10
12秒前
汉堡包的应助被尼古丁真采纳,获得10
12秒前
mu发布了新的文献求助10
13秒前
haha完成签到,获得积分10
13秒前
xj发布了新的文献求助10
14秒前
李佳完成签到,获得积分10
14秒前
yang的应助被科研通管家采纳,获得10
16秒前
fantasy的应助被科研通管家采纳,获得10
16秒前
科研通AI65的应助被科研通管家采纳,获得10
16秒前
元吉的应助被科研通管家采纳,获得10
17秒前
无极微光的应助被科研通管家采纳,获得20
17秒前
Danger完成签到 ,获得积分10
17秒前
SciGPT的应助被科研通管家采纳,获得10
17秒前
17秒前
17秒前
fantasy的应助被科研通管家采纳,获得10
17秒前
脑洞疼的应助被科研通管家采纳,获得10
17秒前
fantasy的应助被科研通管家采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191072
求助须知:如何正确求助?哪些是违规求助? 9578083
关于积分的说明 21856545
捐赠科研通 7790236
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560326
邀请新用户注册赠送积分活动 2483237